Plain-English translation of NCT06652087 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether , an antibiotic that targets bacteria in the small intestine, can help improve heart function in people with a type of heart failure called HFpEF (heart failure with preserved ejection fraction). Researchers believe that bacterial overgrowth in the gut may trigger inflammation that weakens the heart, and treating this overgrowth with the medication might help reduce that inflammation and improve how well your heart works.
More than half of heart failure patients have this specific type (HFpEF), and current treatments are limited. Recent research suggests that an overgrowth of bacteria in the small intestine may be linked to heart damage through inflammation, so doctors want to see if this medication—which safely treats that bacterial overgrowth—could help these patients.
You likely qualify if…
You likely don't qualify if…
You will first have a hydrogen breath test (breathing into a device every 15 minutes for 2 hours) to confirm you have bacterial overgrowth. If you qualify, you will be randomly assigned to either receive the medication for 7 days alongside your regular heart failure treatment, or to continue only your regular treatment without the medication. Researchers will then monitor your heart function and overall health to see if treating the bacterial overgrowth helps.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Russia